Friday, September 30, 2022


Biotechnology News Magazine

Catherine J Mackey, Ph.D. Is Appointed to the Voyager Therapeutics Board of Directors

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Catherine J Mackey, Ph.D. is a seasoned life science executive with more than thirty years of operational experience highlighted by her tenure as Senior Vice President, Global Research & Development, for Pfizer, Inc.

“I am delighted to welcome Catherine to our Board at this pivotal time in Voyager’s evolution,” said Al Sandrock, M.D., Ph.D., chief executive officer of Voyager. “Her outstanding track record of R&D success coupled with her vast expertise in strategic collaborations with industry partners will be invaluable to Voyager as we advance our pipeline and maximize our TRACERTM capsid discovery platform.”

“Voyager is uniquely positioned to help fulfill the vast potential of AAV gene therapy and drive new therapeutic breakthroughs, both with its pipeline and through collaborations with pharma leaders,” remarked Dr. Mackey. “I am pleased to join the Board and look forward to working with Voyager’s leadership team and my fellow Board members to help execute on the company’s commitment to driving scientific advancements with the promise of changing the landscape of AAV gene therapy.”

During her tenure at Pfizer, Dr. Mackey led La Jolla Labs where she oversaw more than 1,000 staff on a one-million square foot campus, delivering a steady-state pipeline of more than two dozen development compounds. Prior to her role at Pfizer La Jolla, Dr. Mackey led Strategic Alliances at its R&D headquarters, where she gained extensive experience with both corporate and academic partnerships in the U.S. and global markets. Additionally, she led Pfizer’s U.S. R&D efforts in Genomic and Proteomic Sciences, which included biomarker and pharmacogenomics research. Dr. Mackey currently serves as a board member for Cour Pharmaceuticals, Avid Bioservices, and IDEAYA Biosciences.

Dr. Mackey, who will join the Voyager’s Board effective on August 15, has been designated as a Class I director with a term ending as of the 2025 annual meeting of Voyager shareholders. Dr. Mackey has also been appointed to the Board’s Audit Committee and Science and Technology Committee.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine